GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » Cash Flow from Financing

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2019, OWC Pharmaceutical Research paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, OWC Pharmaceutical Research spent $0.00 Mil on financial activities for the three months ended in Sep. 2019.


OWC Pharmaceutical Research Cash Flow from Financing Historical Data

The historical data trend for OWC Pharmaceutical Research's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research Cash Flow from Financing Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only 2.10 0.12 0.65 1.69 5.02

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OWC Pharmaceutical Research Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

OWC Pharmaceutical Research's Cash from Financing for the fiscal year that ended in Dec. 2018 is calculated as:

OWC Pharmaceutical Research's Cash from Financing for the quarter that ended in Sep. 2019 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OWC Pharmaceutical Research  (OTCPK:OWCP) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

OWC Pharmaceutical Research's issuance of stock for the three months ended in Sep. 2019 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

OWC Pharmaceutical Research's repurchase of stock for the three months ended in Sep. 2019 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

OWC Pharmaceutical Research's net issuance of debt for the three months ended in Sep. 2019 was $0.00 Mil. OWC Pharmaceutical Research received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

OWC Pharmaceutical Research's net issuance of preferred for the three months ended in Sep. 2019 was $0.00 Mil. OWC Pharmaceutical Research paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

OWC Pharmaceutical Research's cash flow for dividends for the three months ended in Sep. 2019 was $0.00 Mil. OWC Pharmaceutical Research received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

OWC Pharmaceutical Research's other financing for the three months ended in Sep. 2019 was $0.00 Mil. OWC Pharmaceutical Research received $0.00 Mil on other financial activities.


OWC Pharmaceutical Research Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Traded in Other Exchanges
N/A
Address
2 Ben Gurion Street, Ramat Gan, ISR, 5257334
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.
Executives
Asher Zwebner director, officer: CHIEF FINANCIAL OFFICER CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Headlines